In the second 6 months of the study, people who kept taking tesamorelin reduced their visceral fat by nearly 18%, while those who stopped regained the fat quickly, showing a clear cause-and-effect relationship.

Scientific Claim

In a 12-month randomized, double-blind, placebo-controlled trial, continued tesamorelin treatment led to an 18% reduction in visceral adipose tissue, while discontinuation resulted in rapid fat regain, demonstrating a direct and reversible cause-and-effect relationship.

Original Statement

“And I want to come back to this whole IGF one thing. There's something really important with this study because in the second 6 months, some participants stayed on the tesarellin peptide and some switched to placebo. The ones who stayed on timan saw visceral fat reductions approached close to 18%. the ones who stopped regained the fat rapidly. It's a pretty massive clue, right? I mean, this wasn't lifestyle noise. It wasn't a random variation. It was a pretty direct reversible cause and effect relationship.”

From video:The Most Powerful Peptide for Visceral Belly Fat has Been ReleasedbyThomas DeLauer

Context Details

Domain

pharmacology

Population

human

Subject

continued tesamorelin treatment

Action

leads to

Target

18% reduction in visceral adipose tissue and rapid regain upon discontinuation

Intervention Details

Type: drug

Dosage: 2 mg SC daily

Duration: 12 months

Evidence from Studies

Supporting (3)

Unknown Title

Randomized Controlled Trial

Human

The study found that taking tesamorelin for a year shrunk belly fat by 18%, but when people stopped taking it, the fat quickly came back — proving the drug causes the fat loss and it reverses when you stop.

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

Randomized Controlled Trial

Human

2010 Sep

This study shows that tesamorelin not only reduces belly fat in HIV patients but also keeps it reduced as long as the treatment is continued.

Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy

Case-Control Study

Human

2011 Jan

This study confirms that tesamorelin works to reduce belly fat in HIV patients and that the effect stops when the treatment is stopped.

Contradicting (0)

No contradicting evidence found

Similar Assertions

Administration of tesamorelin results in a statistically significant reduction in visceral adipose tissue volume compared to placebo, with a mean reduction of approximately 11% after 6 months of treatment.

89%

In a 6-month randomized, placebo-controlled trial, tesamorelin significantly reduced both visceral and hepatic (liver) fat, with liver fat reduction being particularly important as it improves insulin sensitivity and glucose metabolism.

81%

A daily injection called tesamorelin helps HIV patients on medication lose belly fat inside their abdomen, while a fake shot doesn’t.

80%

Tesamorelin independently increases fat density in visceral and subcutaneous adipose tissue, indicating improved fat quality with smaller adipocytes, better vascularization, reduced hypoxia, and decreased inflammation, independent of fat quantity changes.

78%

For people with HIV and fatty liver who are on INSTI drugs, taking tesamorelin for a year likely reduces belly fat by 8.3%, while those on a placebo see a 10.8% increase in belly fat.

78%